Artificial intelligence is increasingly integral to biotech innovation and healthcare delivery. Google's AlphaGenome model unifies multimodal genomic predictions enhancing variant effect interpretation. Adaptive Biotechnologies partnered with Roche’s Flatiron Health to integrate MRD assay results into electronic medical records, streamlining oncology workflows. AI-driven drug discovery collaborations, such as Healx and SCI Ventures targeting spinal cord injury, aim to accelerate therapeutic development. Concurrently, regulatory agencies are evolving frameworks to incorporate AI in drug manufacturing and oversight with emphasis on agility and continuous learning.